For courses purchased before November 1, 2024, it is suggested that they be completed by December 31, 2024. After this date, disruption in access may occur
Contemporary Anti-Obesity Medications
Contemporary Anti-Obesity Medications
Presented by: John M. Jakicic, Ph.D., FACSM

There have been advancements in the pharmacotherapy treatment options for overweight/obesity, which are commonly referred to as anti-obesity medications (AOMs). This session will explore these AOMs and their effects on body weight, body composition, and other health-related outcomes. Moreover, this session will explore what is currently known about the role of physical activity within the context of AOM treatments and consider opportunities for physical activity within clinical and research settings.

This course was developed using content from ACSM’s 2024 From Around the Field webinar series.

Learner Objectives:
1. To identify current pharmacotherapy treatments for overweight/obesity.
2. To identify the effects of current pharmacotherapy treatments options for overweight/obesity on body weight, body composition, and other health-related outcomes.
3. To identify applied clinical and research opportunities for physical activity within the context of current pharmacotherapy treatments for overweight/obesity.

All course content will be presented to you electronically after your purchase. To earn your CECs, you must view the course content and pass the quiz (earning a 70% or better).

This course expires one year (365 days) from the date of purchase. All course content must be completed prior to the expiration date. ACSM will not offer refunds, transfers or course credits for uncompleted courses prior to their expiration date, or for duplicate purchases. ACSM does not allow substitutions, refunds or credits for this course.

For questions related to your online CEC courses or purchases, email onlinelearning@acsm.org.
Discounted member price: 15.00
30.00
You could save 50.0%
For courses purchased before November 1, 2024, it is suggested that they be completed by December 31, 2024. After this date, disruption in access may occur